Alzheimer's Disease Agents-NMDA Receptor Antagonists

The class of Alzheimer's disease agents designated as N-methyl-D-aspartate (NMDA) receptor antagonists is a category of neuroactive medications designed to mitigate glutamatergic dysfunction in neurodegenerative conditions Therapeutics in this pharmacologic class are primarily indicated for the symptomatic management of moderate to severe Alzheimer's disease to help slow cognitive and functional decline

The class of Alzheimer's disease agents designated as N-methyl-D-aspartate (NMDA) receptor antagonists is a category of neuroactive medications designed to mitigate glutamatergic dysfunction in neurodegenerative conditions These agents, primarily represented by memantine, act as low- to moderate-affinity, uncompetitive open-channel blockers of NMDA receptors to curb chronic, pathological glutamate overstimulation and prevent neurotoxic intracellular calcium overload

These agents, primarily represented by memantine, act as low- to moderate-affinity, uncompetitive open-channel blockers of NMDA receptors to curb chronic, pathological glutamate overstimulation and prevent neurotoxic intracellular calcium overload

At the same time, their rapid receptor kinetics preserve the transient, physiological glutamatergic signaling essential for cognitive processing

At the same time, their rapid receptor kinetics preserve the transient, physiological glutamatergic signaling essential for cognitive processing